ClinicalTrials.gg
RecruitingNCT06804135STIRRUpdated Feb 4, 2026

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

An observational study in Cervical Carcinoma, sponsored by Tata Memorial Hospital. Recruiting at 1 site in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Tata Memorial Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Tata Memorial Hospital.

Planned enrollment
9th of 10
110 · median 325
Started
2025
with 1 other
Observational
10 of 27
6 open now
Registered
22nd of 27
by date

Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2025, is one of 10 observational ones, and was the 22nd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, or all of them as a file.
02

Study summary

Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.

Read the detailed description

This study will be performed using blood and tumor material at different time points and available information from blood tests that have been performed prior to initiating chemoradiation in the institution. The proposed sample size is 110 is a convenience based sampling that is based on estimate of people participating in the study during their radiotherapy course. Participants will be allotted in the cohort as per their radiation treatment plan. Collection of blood and tumor tissue material from participants will happen at different time points. These time points will be decided as per the cohort in whom the patient is. The study intends to investigate immunohistochemical (IHC) expression of PD-L1 on baseline and post-treatment tumor biopsy. Furthermore, the study will also investigate expression of immune cells through flow cytometry - fluorescence-activated cell sorter (FACS) at baseline and after RT on blood and tumor tissue sample. The study also intends to capture radiotherapy information - PTV Dose, HRCTV, Mean liver, spleen, Ileocecal junction dose, TRAK values. Using Analysis of Variance (ANOVA) test, all these parameters will be analyzed against their time points in the individual cohorts and also with other cohorts to provide us a better understanding of how pelvic radiotherapy affects our immune system. Furthermore, the investigators will also use Bonferroni correction test to account for multiple statistical comparison. Most of the research studies in cervical cancer that have been published till date do not utilize various aspects of radiotherapy like dose, dose per fraction, field volumes and techniques. This study will represent the first large cohort focusing on all the above mentioned aspects in cervical cancer patients.

03

Conditions studied

  • Cervical Carcinoma

Keywords

  • Cervical Cancer
  • Immune System
  • Radiotherapy
  • PD-L1 Expression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include patients that are undergoing radiation treatment for primary radiation or reirradiation for cervical cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Common Inclusion Criteria:

    1. Age 18 years and above.
    2. Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
    3. Ability to understand and willingness to sign an document.
    4. Should be willing to undergo extra and blood samples collection for translational research study.

Cohort A:

  1. Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.
  2. Stage IIIB-IVA where palliative RT is indicated for palliative cohort.
  3. No previous irradiation to the pelvis or chemo therapy.

Cohort B:

  1. Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.
  2. No previous irradiation to the pelvis or chemotherapy.

Cohort C:

  1. Patients diagnosed with gynecological cancer and presenting with need of infield radiation.
  2. Planned for reirradiation.

Exclusion criteria

Exclusion Criteria:

  1. Severe medical condition impairing complete treatment delivery.
  2. Patients with states or active infection.
  3. Patients on immunosuppressive drugs for other medical conditions.
  4. Patients who will receive immune checkpoint inhibition (ICI) therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cohort A Pelvic RT - Group 1 Radical Cohort

    n=20 Fractionation Details = 45Gy/25#

  • Cohort A - Group 2 Palliative Arm A

    n=20 Fractionation Details = 25Gy/5#

  • Cohort A - Group 3 Palliative Arm B

    n=20 Fractionation Details = 30Gy/3#

  • Cohort B Pelvic + Para aortic RT Group 4

    n=20 Fractionation Details = 45Gy/25#

  • Cohort C Reirradiation Cohort - Group 5 Proton Therapy

    n=10 Fractionation Details = 40Gy/20#

  • Cohort C Reirradiation Cohort - Group 6 Photon Therapy

    n=10 Fractionation Details = 25-30Gy/5-6#

  • Cohort C Reirradiation Cohort - Group 7 SFRT

    n=10 Fractionation Details = 45Gy/25#

06

What researchers measure

Primary outcomes

  1. To investigate the systemic immune response in patients undergoing radiotherapy for cervical cancer.

    To demonstrate correlation between radiation dose and volume \& systemic immune changes during radiotherapy.

    Time frame: 3 years

  2. To study the multi-time point interaction between radiotherapy for cervical cancer and impact on tumor infiltrating immune cells and PD-L1 expression.

    To demonstrate correlation between radiation dose and volume \& tumor immune changes during radiotherapy.

    Time frame: 3 years

Secondary outcomes

  1. To study 3-year disease free survival as a function of baseline and post radiotherapy immune cell composition.

    To determine association of disease-free survival and clinical outcomes with baseline and post radiotherapy immune cell composition.

    Time frame: 3 years from last date of treatment and/or to date of reccurrence/relapse

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 38 months after the start.

Of 190 non-industry observational studies under Uterine Cervical Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 158. This study's planned 38 months is below that.

Counting every sponsor, half of 214 studies reached it within 58 months; a quarter within 28 and three quarters within 158.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 3, 2025
StartActual
Oct 25, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 30, 2030
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804135
Lead sponsor
Tata Memorial Hospital
Responsible party
Supriya Sastri (chopra) (Professor, Radiation Oncology, Tata Memorial Centre) — Principal investigator
First posted
Feb 3, 2025
Start date
Oct 25, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Feb 4, 2026

Study contacts

Dr. Supriya Chopra
Contact
supriyasastri@gmail.com
+022-68735000 ext. 5113
Mr. Tanmay Wairkar
Contact
wairkartanmay@yahoo.com
+918879299557

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion